ECSP013952A - CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE - Google Patents
CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINEInfo
- Publication number
- ECSP013952A ECSP013952A EC2001003952A ECSP013952A ECSP013952A EC SP013952 A ECSP013952 A EC SP013952A EC 2001003952 A EC2001003952 A EC 2001003952A EC SP013952 A ECSP013952 A EC SP013952A EC SP013952 A ECSP013952 A EC SP013952A
- Authority
- EC
- Ecuador
- Prior art keywords
- oral administration
- ciprofloxacine
- administration system
- daily intake
- controlled oral
- Prior art date
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003405 ciprofloxacin Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000001879 gelation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Es una fórmula contenida en una tableta diaria para administración oral a humanos para la liberación controlada de Ciprofloxacina, que comprende una cantidad de ciprofloxacina farmacéuticamente efectiva, desde alrededor de 0.1% hasta alrededor de 8.0% de una gente viscolizante y/o un agente de gelación, alrededor de 5.0% hasta alrededor de 15% de un agente generador de gas (efervescencia) y alrededor de 3.0% hasta alrededor de 15% de un agente de expansión, estando dichos porcentajes en relación de peso/peso del compuesto.It is a formula contained in a daily tablet for oral administration to humans for the controlled release of Ciprofloxacin, which comprises a pharmaceutically effective amount of ciprofloxacin, from about 0.1% to about 8.0% of a viscolizing people and / or a gelation agent. , about 5.0% to about 15% of a gas generating agent (effervescence) and about 3.0% to about 15% of an expanding agent, said percentages being in weight / weight ratio of the compound.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51788700A | 2000-03-03 | 2000-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP013952A true ECSP013952A (en) | 2002-04-23 |
Family
ID=24061635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2001003952A ECSP013952A (en) | 2000-03-03 | 2001-03-01 | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1263409A1 (en) |
| JP (1) | JP2003525229A (en) |
| KR (1) | KR20030009374A (en) |
| CN (1) | CN1420763A (en) |
| AP (2) | AP2001002084A0 (en) |
| AR (1) | AR032614A1 (en) |
| AU (1) | AU3589701A (en) |
| BG (1) | BG107055A (en) |
| BR (1) | BR0108958A (en) |
| CA (1) | CA2400950A1 (en) |
| CZ (1) | CZ20022883A3 (en) |
| DO (1) | DOP2001000130A (en) |
| EA (1) | EA200200914A1 (en) |
| EC (1) | ECSP013952A (en) |
| EE (1) | EE200200497A (en) |
| GT (1) | GT200100033A (en) |
| HN (1) | HN2001000038A (en) |
| HR (1) | HRP20020715A2 (en) |
| HU (1) | HUP0204417A3 (en) |
| IL (1) | IL151553A0 (en) |
| IS (1) | IS6532A (en) |
| MX (1) | MXPA02008568A (en) |
| NO (1) | NO20024108L (en) |
| NZ (1) | NZ520927A (en) |
| OA (1) | OA12381A (en) |
| PE (1) | PE20011113A1 (en) |
| PL (1) | PL365071A1 (en) |
| SK (1) | SK12542002A3 (en) |
| WO (1) | WO2001064183A1 (en) |
| YU (1) | YU66202A (en) |
| ZA (1) | ZA200206764B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20030229101A1 (en) * | 2002-06-06 | 2003-12-11 | Sherman Bernard Charles | Tablets comprising ciprofloxacin hydrochloride |
| DE10351448A1 (en) | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Flavor-containing drug formulations with improved pharmaceutical properties |
| EP1745775B1 (en) * | 2005-07-19 | 2008-05-28 | Ethypharm | Gastroretentive formulations and manufacturing process thereof. |
| ATE460934T1 (en) * | 2006-07-19 | 2010-04-15 | Tabuk Pharmaceutical Mfg Co | PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN |
| EP3247384B1 (en) | 2015-01-14 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | In vitro method of diagnosis of type 1 diabetes with insulin mimotopes |
| CA3015400C (en) * | 2016-02-23 | 2024-10-29 | Matripharm International Inc. | Dual-rate release formulation with high drug loading |
| WO2017165508A1 (en) | 2016-03-24 | 2017-09-28 | Im Therapeutics | Methods of treating autoimmune disease |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN109806237A (en) * | 2019-03-13 | 2019-05-28 | 悦康药业集团上海制药有限公司 | A kind of Ciprofloxacin Lactate effervescent tablet and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0624959A (en) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | Medice release solid pharmaceutical preparation of gastric suspending type sustained |
| DE4406424A1 (en) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandable dosage forms |
| DE19839057A1 (en) * | 1998-08-28 | 2000-03-02 | Koch Berthold | Purge air controller for a drying device for compressed air |
| HUP0103632A3 (en) * | 1998-09-14 | 2005-06-28 | Ranbaxy Lab Ltd | Orally administered controlled drug delivery system providing temporal and spatial control |
-
2001
- 2001-02-28 EP EP01908038A patent/EP1263409A1/en not_active Withdrawn
- 2001-02-28 WO PCT/IB2001/000279 patent/WO2001064183A1/en not_active Ceased
- 2001-02-28 OA OA1200200267A patent/OA12381A/en unknown
- 2001-02-28 JP JP2001563081A patent/JP2003525229A/en not_active Withdrawn
- 2001-02-28 MX MXPA02008568A patent/MXPA02008568A/en unknown
- 2001-02-28 EA EA200200914A patent/EA200200914A1/en unknown
- 2001-02-28 AR ARP010100957A patent/AR032614A1/en not_active Application Discontinuation
- 2001-02-28 NZ NZ520927A patent/NZ520927A/en unknown
- 2001-02-28 AP APAP/P/2001/002084A patent/AP2001002084A0/en unknown
- 2001-02-28 CA CA002400950A patent/CA2400950A1/en not_active Abandoned
- 2001-02-28 HR HRP20020715 patent/HRP20020715A2/en not_active Application Discontinuation
- 2001-02-28 BR BR0108958-7A patent/BR0108958A/en not_active IP Right Cessation
- 2001-02-28 KR KR1020027011441A patent/KR20030009374A/en not_active Ceased
- 2001-02-28 YU YU66202A patent/YU66202A/en unknown
- 2001-02-28 CZ CZ20022883A patent/CZ20022883A3/en unknown
- 2001-02-28 SK SK1254-2002A patent/SK12542002A3/en unknown
- 2001-02-28 AU AU35897/01A patent/AU3589701A/en not_active Abandoned
- 2001-02-28 IL IL15155301A patent/IL151553A0/en unknown
- 2001-02-28 CN CN01805998A patent/CN1420763A/en active Pending
- 2001-02-28 AP APAP/P/2002/002627A patent/AP1485A/en active
- 2001-02-28 EE EEP200200497A patent/EE200200497A/en unknown
- 2001-02-28 HU HU0204417A patent/HUP0204417A3/en unknown
- 2001-02-28 PL PL01365071A patent/PL365071A1/en not_active Application Discontinuation
- 2001-03-01 PE PE2001000206A patent/PE20011113A1/en not_active Application Discontinuation
- 2001-03-01 GT GT200100033A patent/GT200100033A/en unknown
- 2001-03-01 EC EC2001003952A patent/ECSP013952A/en unknown
- 2001-03-02 DO DO2001000130A patent/DOP2001000130A/en unknown
- 2001-03-02 HN HN2001000038A patent/HN2001000038A/en unknown
-
2002
- 2002-08-23 ZA ZA200206764A patent/ZA200206764B/en unknown
- 2002-08-28 NO NO20024108A patent/NO20024108L/en unknown
- 2002-08-28 IS IS6532A patent/IS6532A/en unknown
- 2002-09-02 BG BG107055A patent/BG107055A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA12381A (en) | 2004-09-06 |
| CA2400950A1 (en) | 2001-09-07 |
| IL151553A0 (en) | 2003-04-10 |
| WO2001064183A1 (en) | 2001-09-07 |
| NO20024108L (en) | 2002-10-25 |
| HN2001000038A (en) | 2005-03-23 |
| EA200200914A1 (en) | 2003-02-27 |
| EP1263409A1 (en) | 2002-12-11 |
| MXPA02008568A (en) | 2003-02-24 |
| IS6532A (en) | 2002-08-28 |
| CN1420763A (en) | 2003-05-28 |
| EE200200497A (en) | 2004-02-16 |
| SK12542002A3 (en) | 2003-05-02 |
| HUP0204417A3 (en) | 2005-03-29 |
| AU3589701A (en) | 2001-09-12 |
| KR20030009374A (en) | 2003-01-29 |
| BG107055A (en) | 2003-06-30 |
| PE20011113A1 (en) | 2001-10-14 |
| PL365071A1 (en) | 2004-12-27 |
| GT200100033A (en) | 2001-10-25 |
| HUP0204417A2 (en) | 2003-05-28 |
| JP2003525229A (en) | 2003-08-26 |
| BR0108958A (en) | 2003-09-30 |
| ZA200206764B (en) | 2003-03-04 |
| DOP2001000130A (en) | 2004-03-31 |
| NO20024108D0 (en) | 2002-08-28 |
| NZ520927A (en) | 2003-06-30 |
| AR032614A1 (en) | 2003-11-19 |
| CZ20022883A3 (en) | 2003-04-16 |
| AP1485A (en) | 2005-10-31 |
| AP2001002084A0 (en) | 2001-03-31 |
| HRP20020715A2 (en) | 2004-12-31 |
| AP2002002627A0 (en) | 2002-09-30 |
| YU66202A (en) | 2005-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035927A1 (en) | LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR | |
| ECSP013952A (en) | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE | |
| CY1105908T1 (en) | BENZIMIDAZOLE ORODICALLY DISPERSIBLE TABLETS | |
| BR0313424A (en) | Dosage form and process for preparing a dosage form | |
| HRP20030951B1 (en) | FORMULATIONS OF ONE-DAY DOSAGE OF OXYCODONE | |
| ATE333265T1 (en) | RAPIDLY DISSOLVING SOLID DOSAGE FORMS FOR ORAL APPLICATION | |
| BR0215184A (en) | orally active taxane derivative pharmaceutical compositions having increased bioavailability | |
| AR033444A1 (en) | SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT | |
| BR9808888A (en) | Dosage forms and method of improving male erectile dysfunction | |
| ES2156028T3 (en) | Compositions containing tetrahydrolipstatin | |
| HUP9901710A2 (en) | New, stable medicinal compositions for generating propellant-free aerosols | |
| WO2002038208A3 (en) | Device and method for the cessation of smoking | |
| IS5283A (en) | Pharmaceutical formulations containing eletriptan hemisulfate and caffeine | |
| TW200633730A (en) | Oral disintegrating dosage forms | |
| CO5280073A1 (en) | COMPOSITIONS | |
| ATE298324T1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| BR0209283A (en) | Method for the manufacture of a low dosage pharmaceutical composition having uniform drug distribution and potency | |
| NO20055880L (en) | Memantine oral dosage forms | |
| PT1425005E (en) | PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS LUMIRACOXIB | |
| AR021806A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES ENTACAPONA AND METHOD OF PREPARATION. | |
| SE0000774D0 (en) | New formulation | |
| MY129314A (en) | Pharmaceutical composition comprising sumatriptan | |
| PL402550A1 (en) | Intravaginal pharmaceutical composition and the use of a peroxide source and a bioadhesive carrier | |
| CO5200850A1 (en) | PHARMACEUTICAL COMPOSITION FOR PROFILAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH THE FLU, INFLUENZA AND SIMILAR DISEASES AND PROCEDURE FOR APPLICATION | |
| BR0307320A (en) | Osmotic release system |